



**FOR IMMEDIATE RELEASE**

### **ZHAOKE New Facility in Hefei Received GMP Approval by CFDA**

Hong Kong, 26<sup>th</sup> February 2014 – Lee's Pharmaceutical Holdings Limited ("the Group" or "Lee's") (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that Zhaoke Pharmaceutical (Hefei) Co., Ltd. ("Zhaoke"), the Group's wholly-owned subsidiary has obtained the new GMP certification for its new manufacturing facility in Hefei city of China.

In 2011, China Food and Drug Administration ("CFDA") enacted the new Good Manufacturing Practice (GMP) regulation and mandated that all aseptic manufacturing facilities must meet the new standard by end of 2013. Non-complied facilities must cease production by end of December. Starting 2011, the Group has invested nearly 100 million RMB and erected a new manufacturing facility in Zhaoke Pharmaceutical (Hefei) Co., Ltd.'s premise. The facility is equipped with state-of-art production line with high degree of automation. It significantly augments the Group's production capacity for all available dosage forms and provides greater assurance in product quality. The facilities were inspected by the CFDA auditors in late December 2013 and early January 2014, and were found conforming to the new GMP standard. As today, all five dosage forms such as small volume for injection, lyophilized powder for injection, topical gel of  $\alpha$  2b-interferon, eye gel and low molecular weight heparin API are certified by CFDA for a validity of five years.

"We are thrilled of reaching this great milestone. The new GMP version implemented by the CFDA is similar to the GMP in US and EU. The attainment of this standard is testimony of the improvement of our quality control system," said Dr. Benjamin Li, Chief Executive Officer of the Company. "We are especially proud of our team work displayed during the last two years' efforts."

#### **About Lee's Pharmaceutical**

**Lee's Pharmaceutical Holdings Limited** is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at [www.leespharm.com](http://www.leespharm.com).



---

**FOR IMMEDIATE RELEASE**

**Safe Harbor Statement**

*The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*